-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Genesis Therapeutics announced today that it has partnered with Eli Lilly and Company to leverage Genesis’ artificial intelligence (AI) drug discovery platform to discover innovative treatments for up to five targets across multiple therapeutic areas
.
Under the agreement, scientists from Genesis and Eli Lilly will jointly use Genesis' AI drug discovery platform to develop potential "first-in-class" and "best-in-class" drug candidates against three targets
.
Genesis will receive an upfront payment of $20 million, and Lilly has the option to add two additional targets
.
Genesis, meanwhile, is eligible to receive up to $670 million in up-front and milestone payments
.
It is understood that in the context of the continuous improvement and development of artificial intelligence (AI) technology, more and more pharmaceutical companies have begun to use AI technology to deploy new drug research and development, shorten the research and development cycle, save compound screening costs and clinical trial costs, and improve drug research and development.
success rate
.
Among them, Lilly is one of the main representatives
.
In recent years, Lilly has been making continuous moves in the field of AI.
For example, as early as December 2021, Shanghai Qilu Ruige Pharmaceutical Research and Development Co.
, Ltd.
(hereinafter referred to as "Ruige Medicine") reached a cooperation with Lilly.
The two parties will cooperate in the next few years.
Collaborate closely in preclinical drug development, clinical research and commercialization to jointly develop innovative treatments for metabolic diseases
.
In this cooperation, Ruige Pharmaceuticals will grant an intellectual property license to Lilly and Lilly in the United States, and Lilly will be responsible for clinical development, production and Commercialization; Riage Pharma will retain the above interests in Greater China
.
Ruige Pharma will receive an upfront payment of a total of $50 million, including a partial equity investment
.
In addition, Riage Pharma will receive up to $1.
5 billion in potential preclinical, clinical development and commercialization milestone payments, as well as a single-digit to low-double-digit global sales share
.
It is worth noting that the relevant person in charge said that this cooperation is a recognition of the core technology and research capabilities of Ruige Medicine.
.
It is reported that Ruige Medicine is a high-tech biopharmaceutical company in the clinical stage.
It will use its AI-assisted R&D CARD (Computer Accelerated Rational Discovery) platform to target the "long-term" targets in the pharmaceutical industry and develop clinical differentiation advantages.
It focuses on the three major therapeutic areas of oncology, immunity and metabolism
.
Previously, the company has received $90 million in Series B financing led by Eli Lilly Asia Fund
.
In addition, on November 7, 2020, during the 3rd China International Import Expo, Lilly China, Beijing Changjiang Pharmaceutical Development Foundation and Shanghai Eagle Eye Medical Technology Co.
, Ltd.
(hereinafter referred to as Airdoc) also chose to jointly Join hands to officially launch the psoriasis artificial intelligence simulation and management project
.
It is reported that the health innovation project aims to use artificial intelligence technology to provide a one-stop full-course management solution for the majority of psoriasis patients in China, from auxiliary diagnosis to disease simulation, monitoring and scoring, and create a new "full-course intelligent management of psoriasis".
mode
.
Looking at the world, in addition to Eli Lilly, a large number of domestic and foreign companies such as Novartis, Pfizer, GSK, AstraZeneca, Sanofi, Fosun Pharma, Qihui Bio have also tested the water to develop new drugs with AI, and continue to compete in AI pharmaceutical competition.
Road siege city slightly pool
.
For example, not long ago, Nhwa Pharmaceutical and Shenshi Technology reached a strategic cooperation agreement, and the two parties jointly promoted Nhwa Pharmaceutical's research and development of small molecule innovative drugs in the central nervous system
.
At the same time, the two parties will further explore the advantages of cooperation, combine AI technology and innovative molecular research and development more widely, and accelerate and expand the research and development process and innovation dimension of drugs in the central nervous system
.
For this cooperation, Shenshi Technology said that it will deeply integrate the computing paradigm based on 'AI + molecular simulation' into the actual cooperative research and development project, and jointly create a research and development model of 'computing design-experimental verification', looking forward to accelerating the development of the central nervous system.
New drug development brings more new results
.
It should be noted that with more and more companies entering the game, the current AI pharmaceutical track is very hot
.
For example, the domestic AI pharmaceutical financing boom is on the rise
.
According to data, there will be 34 financing events in the domestic AI pharmaceutical industry in 2021, with a total financing amount exceeding 8 billion yuan
.
Entering 2022, this track is advancing by leaps and bounds.
In the first quarter of 2022, there will be more than 10 new financings, involving Xihu Omi, Xinhua Bio, Lemang Bio, Shenshi Technology, Yudao Bio, Yiyao Technology, and Kehui Zhiyao.
and other enterprises
.
The industry believes that, at present, the domestic AI pharmaceutical market will continue to be hot.
While the competition for new drug research and development is intensifying, drug research and development innovation is expected to continue to accelerate, and with the continuous emergence of innovative results, more and more patients will be There may be more options for treatment
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Under the agreement, scientists from Genesis and Eli Lilly will jointly use Genesis' AI drug discovery platform to develop potential "first-in-class" and "best-in-class" drug candidates against three targets
.
Genesis will receive an upfront payment of $20 million, and Lilly has the option to add two additional targets
.
Genesis, meanwhile, is eligible to receive up to $670 million in up-front and milestone payments
.
It is understood that in the context of the continuous improvement and development of artificial intelligence (AI) technology, more and more pharmaceutical companies have begun to use AI technology to deploy new drug research and development, shorten the research and development cycle, save compound screening costs and clinical trial costs, and improve drug research and development.
success rate
.
Among them, Lilly is one of the main representatives
.
In recent years, Lilly has been making continuous moves in the field of AI.
For example, as early as December 2021, Shanghai Qilu Ruige Pharmaceutical Research and Development Co.
, Ltd.
(hereinafter referred to as "Ruige Medicine") reached a cooperation with Lilly.
The two parties will cooperate in the next few years.
Collaborate closely in preclinical drug development, clinical research and commercialization to jointly develop innovative treatments for metabolic diseases
.
In this cooperation, Ruige Pharmaceuticals will grant an intellectual property license to Lilly and Lilly in the United States, and Lilly will be responsible for clinical development, production and Commercialization; Riage Pharma will retain the above interests in Greater China
.
Ruige Pharma will receive an upfront payment of a total of $50 million, including a partial equity investment
.
In addition, Riage Pharma will receive up to $1.
5 billion in potential preclinical, clinical development and commercialization milestone payments, as well as a single-digit to low-double-digit global sales share
.
It is worth noting that the relevant person in charge said that this cooperation is a recognition of the core technology and research capabilities of Ruige Medicine.
.
It is reported that Ruige Medicine is a high-tech biopharmaceutical company in the clinical stage.
It will use its AI-assisted R&D CARD (Computer Accelerated Rational Discovery) platform to target the "long-term" targets in the pharmaceutical industry and develop clinical differentiation advantages.
It focuses on the three major therapeutic areas of oncology, immunity and metabolism
.
Previously, the company has received $90 million in Series B financing led by Eli Lilly Asia Fund
.
In addition, on November 7, 2020, during the 3rd China International Import Expo, Lilly China, Beijing Changjiang Pharmaceutical Development Foundation and Shanghai Eagle Eye Medical Technology Co.
, Ltd.
(hereinafter referred to as Airdoc) also chose to jointly Join hands to officially launch the psoriasis artificial intelligence simulation and management project
.
It is reported that the health innovation project aims to use artificial intelligence technology to provide a one-stop full-course management solution for the majority of psoriasis patients in China, from auxiliary diagnosis to disease simulation, monitoring and scoring, and create a new "full-course intelligent management of psoriasis".
mode
.
Looking at the world, in addition to Eli Lilly, a large number of domestic and foreign companies such as Novartis, Pfizer, GSK, AstraZeneca, Sanofi, Fosun Pharma, Qihui Bio have also tested the water to develop new drugs with AI, and continue to compete in AI pharmaceutical competition.
Road siege city slightly pool
.
For example, not long ago, Nhwa Pharmaceutical and Shenshi Technology reached a strategic cooperation agreement, and the two parties jointly promoted Nhwa Pharmaceutical's research and development of small molecule innovative drugs in the central nervous system
.
At the same time, the two parties will further explore the advantages of cooperation, combine AI technology and innovative molecular research and development more widely, and accelerate and expand the research and development process and innovation dimension of drugs in the central nervous system
.
For this cooperation, Shenshi Technology said that it will deeply integrate the computing paradigm based on 'AI + molecular simulation' into the actual cooperative research and development project, and jointly create a research and development model of 'computing design-experimental verification', looking forward to accelerating the development of the central nervous system.
New drug development brings more new results
.
It should be noted that with more and more companies entering the game, the current AI pharmaceutical track is very hot
.
For example, the domestic AI pharmaceutical financing boom is on the rise
.
According to data, there will be 34 financing events in the domestic AI pharmaceutical industry in 2021, with a total financing amount exceeding 8 billion yuan
.
Entering 2022, this track is advancing by leaps and bounds.
In the first quarter of 2022, there will be more than 10 new financings, involving Xihu Omi, Xinhua Bio, Lemang Bio, Shenshi Technology, Yudao Bio, Yiyao Technology, and Kehui Zhiyao.
and other enterprises
.
The industry believes that, at present, the domestic AI pharmaceutical market will continue to be hot.
While the competition for new drug research and development is intensifying, drug research and development innovation is expected to continue to accelerate, and with the continuous emergence of innovative results, more and more patients will be There may be more options for treatment
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
